|Title:||Submaximal Exercise Testing in People with Cystic Fibrosis (PWCF) Pre and Post ‘Kaftrio®’ at Beaumont Hospital Cystic Fibrosis (CF) Centre|
|Author(s):||A.Murphy L.Cullen M.Casey C.Gunaratnam N.G.McElvaney|
|Poster:||Click to view poster|
|Category:||CF and Pulmonary Infections|
|Abstract:||In the absence of cardiopulmonary exercise testing facilities, the submaximal Modified Shuttle Walk Test (MSWT) is used in Beaumont Hospital for PWCF to assess exercise capacity annually1 2 and to monitor other clinical interventions, e.g. response to new modulator therapies. 1 |
Baseline MSWT data was captured and 10 PWCF (mean FEV1= 62.4%) were retested within six months of starting ‘Kaftrio®’. Pre and post ‘Kaftrio®’ MSWT results were compared and analysed.
Within six months of starting ‘Kaftrio®’ statistically significant improvements were noted in FEV1% (p=0.0084), weight (p<0.0001), resting oxygen saturation levels (p=0.0176) and MSWT distance (p=0.0112), with a mean increase of 100 metres. There was no significant difference in resting heart rate and BORG scores remain unchanged.
4 additional patients (mean FEV1= 74.75%) completed the MSWT prior to starting ‘Kaftrio®’. This ceiling effect could be highlighted further as patients with milder disease transition to ‘Kaftrio®’, thus potentially limiting the value of MSWT in the modulator era.
These results highlight the benefit of exercise testing in assessing clinical response to modulator therapies. Furthermore these results emphasise the need for maximal exercise testing when assessing clinical response in PWCF with milder disease.